Japanese approval boosts Novo’s fight for market shares
According to Sydbank, the rapid approval of Novo Nordisk’s new insulin in Japan could have a positive effect on the company’s decline in market shares. Moreover, it sends an important signal to the rest of the world.
Novo Nordisks Japanese market share will hopefully benefit from the fast approval of the company’s new insulin Tresiba, says Sydbank, after an expert committee recommended Japanese health authorities to approve the drug last week.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
